Hims & Hers and the Compounded GLP-1 Market
Telehealth company Hims & Hers Health (NYSE: HIMS) stands poised to maintain its offering of compounded semaglutide, an obesity treatment, despite fresh developments from US regulators indicating there isn't a shortage of a comparable product. This is based on insights from analysts at Canaccord Genuity.
Market Dynamics and Recent Developments
Just last week, shares of Hims & Hers experienced a downturn following a report from federal drug regulators regarding Eli Lilly (NYSE: LLY) and its popular weight-loss medications. The announcement stated that these drugs are no longer in short supply, creating a ripple effect in the market.
Major pharmaceutical firms such as Eli Lilly and its rival Novo Nordisk (NYSE: NVO) are grappling with an overwhelming surge in demand for GLP-1 medications. These drugs have been impactful, as some patients report losing as much as 20% of their body weight on average while under treatment.
Why Hims & Hers is Unique in the Market
Owing to the ongoing shortage, the US has permitted various companies to produce compounded versions of brand-name drugs. Hims & Hers is one of those companies, providing semaglutide injections for $199 monthly on a 12-month plan on its website. Interestingly, they recently stated plans to offer a version of Wegovy for only $99 a month to specific professionals.
Impact of FDA Announcements on Hims & Hers' Strategy
In a turn of events, the FDA declared recently that tirzepatide is no longer classified as being in short supply. This medication, marketed by Eli Lilly as Zepbound for weight loss and Mounjaro for diabetes, was initially identified as scarce back in 2022. However, analysts suggested that this development would not directly influence Hims & Hers because they specialize in compounding semaglutide, which is still on the FDA's shortage list.
Future Outlook and Market Potential
Despite the FDA's comments, which could limit Hims & Hers's market reach, Canaccord Genuity analysts remain optimistic. They highlighted that the challenges associated with Wegovy, including potential side effects for certain individuals, could allow Hims & Hers to provide personalized dosing strategies to cater to patient-specific needs.
The analysts suggested that the demand for compounded GLP-1 medications might evolve into a specialized yet considerable segment of the health market. This perspective led them to maintain a “Buy” rating for Hims & Hers, with a projected price target of $24.
Frequently Asked Questions
What is the focus of Hims & Hers Health?
Hims & Hers Health focuses on providing telehealth services and personalized medication options, including compounded treatments for obesity.
What is semaglutide?
Semaglutide is a medication designed to aid in weight loss and management of type 2 diabetes, often involved in the GLP-1 class of drugs.
Why is there a growing interest in compounded GLP-1 medications?
The rising interest is largely due to persistent drug shortages and the desire for personalized treatment options tailored to individual needs.
How does Hims & Hers differentiate itself in the market?
Hims & Hers distinguishes itself by offering customized dosing and compounded versions of popular weight loss medications not currently available in standard supply.
What is the analyst outlook for Hims & Hers?
Analysts from Canaccord Genuity have a positive outlook, maintaining a “Buy” rating with a target price set at $24 amid the evolving market dynamics.
